Pfizer (PFE) is a research-based biopharmaceutical company that operates two business segments—Innovative Health and Essential Health. The chart below compares the changes in analysts’ recommendations for Pfizer stock since January.
Stock price performance
Pfizer’s (PFE) stock price has increased ~8.0% over the last month, and its stock price has risen ~24.0% over the last 12 months. PFE stock has risen 14.6% year-to-date. Analysts’ estimates show that the stock could rise ~0.7% over the next 12 months.
Wall Street analysts’ recommendations show a 12-month target price of $41.80 per share, compared to its price of $41.50 per share on August 28.
Of the 21 analysts tracking Pfizer stock on August 29, one analyst recommended a “strong buy.” Nine analysts recommended a “buy,” eight analysts recommended a “hold,” and three analysts recommended a “strong sell” for Pfizer stock. The consensus rating for Pfizer stands at 2.76, representing a “hold” for investors.
Pfizer was trading at a forward PE multiple of ~13.6x on August 29, compared to the industry average of ~15.9x. On a capital structure–neutral basis, Pfizer trades at a forward EV-to-EBITDA multiple of ~11.8x, which is lower than the industry’s average of ~12.2x on August 29.